@article {Fan2021.03.11.21253287, author = {Lei Fan and Xiangzhu Zhu and Yinan Zheng and Wei Zhang and Douglas L Seidner and Reid Ness and Harvey J Murff and Chang Yu and Xiang Huang and Martha J Shrubsole and Lifang Hou and Qi Dai}, title = {Magnesium Treatment on Methylation Changes of Transmembrane Serine Protease 2 (TMPRSS2)}, elocation-id = {2021.03.11.21253287}, year = {2021}, doi = {10.1101/2021.03.11.21253287}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background The viral entry of SARS-CoV-2 requires host-expressed TMPRSS2 to facilitate the viral spike (S) protein priming.Objectives To test the hypothesis that Mg treatment leads to DNA methylation changes in TMPRSS2.Methods This study is nested within the Personalized Prevention of Colorectal Cancer Trial (PPCCT), a double-blind 2{\texttimes}2 factorial randomized controlled trial, which enrolled 250 participants from Vanderbilt University Medical Center. Target doses for both Mg and placebo arms were personalized.Results We found that 12-week of personalized Mg treatment significantly increased 5-mC methylation at cg16371860 (TSS1500, promoter) by 7.2\% compared to placebo arm (decreased by 0.1\%) in those aged \< 65 years old. The difference remained statistically significant after adjusting for age, sex and baseline methylation as well as FDR correction (FDR-adjusted P =0.014). Additionally, Mg treatment significantly reduced 5-hmC level at cg26337277 (close proximity to TSS200 and 5{\textquoteright}UTR, promoter) by 2.3\% compared to increases by 7.1\% in the placebo arm after adjusting for covariates in those aged \< 65 years old (P=0.003). The effect remained significant at FDR of 0.10 (adjusted P value=0.088).Conclusion Among individuals aged younger than 65 years with the Ca:Mg intake ratios equal to or over 2.6, reducing Ca:Mg ratios to around 2.3 increased 5-mC modifications (i.e. cg16371860) and reduced 5-hmC modifications (i.e. cg26337277) in the TMPRSS2 gene. These findings, if confirmed, provide another mechanism for the role of Mg intervention for the prevention of COVID-19 and treatment of early and mild disease by modifying the phenotype of the TMPRSS2 genotype.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe Personalized Prevention of Colorectal Cancer Trial (PPCCT) was registered at clinicaltrials.gov as NCT01105169.Funding StatementThis study was supported by R01 CA149633 (to Qi Dai and Chang Yu) and R01 CA202936 (to Qi Dai and Lifang Hou) from the National Cancer Institute, Department of Health and Human Services as well as the Ingram Cancer Center Endowment Fund. Data collection, sample storage and processing for this study were partially conducted by the Survey and Biospecimen Shared Resource, which is supported in part by P30CA68485. Clinical visits to the Vanderbilt Clinical Research Center were supported in part by the Vanderbilt CTSA grant UL1 RR024975 from NCRR/NIH. The parent study data were stored in Research Electronic Data Capture (REDCap) and data analyses (VR12960) were supported in part by the Vanderbilt Institute for Clinical and Translational Research (UL1TR000445).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All study procedures were performed in accordance with relevant guidelines and regulations as approved by the Vanderbilt Institutional Review Board. The study is registered at ClinicalTrials.gov (NCT01105169).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data have been deposited to the NIH database of Genotypes and Phenotypes (dbGaP).}, URL = {https://www.medrxiv.org/content/early/2021/03/12/2021.03.11.21253287}, eprint = {https://www.medrxiv.org/content/early/2021/03/12/2021.03.11.21253287.full.pdf}, journal = {medRxiv} }